The Effect of Gut Microbiota Alteration, Probiotic Supplementation, and the Ketogenic Diet on Alzheimer’s Disease Symptoms
DOI:
https://doi.org/10.58445/rars.3562Keywords:
probiotic supplementation, microbiota, ketogenic diet, Alzheimer's diseaseAbstract
Alzheimer’s disease (AD) is a complex neurodegenerative disease that is shaped by several different inherent and lifestyle factors. Diet has the potential in modulating AD through gut microbiota modulation. In this review, we discuss how the gut microbiota impacts AD symptoms. Furthermore, we investigate the ability of two specific aspects of diet rising in popularity, probiotic supplementation and the ketogenic diet, to alter the gut microbiota and improve symptoms and biomarkers of AD. We hope that increased knowledge of how dietary adjustment affects AD can lead to novel treatments or key prevention methods for AD in the future.
References
Abdul Manan, Musaalbakri. “The role of probiotics in personalized therapeutics: Advances in gut microbe-driven interventions.” The Microbe, vol. 8, Sept. 2025, p. 100497, https://doi.org/10.1016/j.microb.2025.100497.
Akhgarjand, Camellia, et al. “The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled study.” Inflammopharmacology, vol. 32, no. 2, 6 Feb. 2024, pp. 1413–1420, https://doi.org/10.1007/s10787-023-01427-2.
Bamford, Rosemary A., et al. “The interaction between contactin and amyloid precursor protein and its role in Alzheimer's disease.” Neuroscience, vol. 424, Jan. 2020, pp. 184–202, https://doi.org/10.1016/j.neuroscience.2019.10.006.
Bloom, George S. “Amyloid-β and tau.” JAMA Neurology, vol. 71, no. 4, 1 Apr. 2014, p. 505, https://doi.org/10.1001/jamaneurol.2013.5847.
Brothers, Holly M., et al. “The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer's disease.” Frontiers in Aging Neuroscience, vol. 10, 25 Apr. 2018, https://doi.org/10.3389/fnagi.2018.00118.
Brownlow, Milene L., et al. “Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology.” PLoS ONE, vol. 8, no. 9, 12 Sept. 2013, https://doi.org/10.1371/journal.pone.0075713.
Cao, Qingyu, et al. “Elucidating the specific mechanisms of the gut-brain axis: The short-chain fatty acids-microglia pathway.” Journal of Neuroinflammation, vol. 22, no. 1, 21 May 2025, https://doi.org/10.1186/s12974-025-03454-y.
Carabotti, Marilia, et al. “The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.” Annals of Gastroenterology, vol. 28, no. 2, 2016, pp. 203–209.
Chen, Yijun, and Yang Yu. “Tau and neuroinflammation in alzheimer’s disease: Interplay mechanisms and clinical translation.” Journal of Neuroinflammation, vol. 20, no. 1, 14 July 2023, https://doi.org/10.1186/s12974-023-02853-3.
Chow, Vivian W., et al. “An overview of APP processing enzymes and products.” NeuroMolecular Medicine, vol. 12, no. 1, 24 Nov. 2009, pp. 1–12, https://doi.org/10.1007/s12017-009-8104-z.
Colonna, Marco, and Oleg Butovsky. “Microglia function in the central nervous system during health and neurodegeneration.” Annual Review of Immunology, vol. 35, no. 1, 26 Apr. 2017, pp. 441–468, https://doi.org/10.1146/annurev-immunol-051116-052358.
“Donanemab for Treatment of Early Alzheimer’s.” Alzheimer’s Association, www.alz.org/alzheimers-dementia/treatments/donanemab. Accessed 20 Dec. 2025.
Elangovan, Shalini, et al. “Fecal microbiota transplantation reduces pathology and improves cognition in a mouse model of Alzheimer's disease.” Cells, vol. 12, no. 1, 28 Dec. 2022, p. 119, https://doi.org/10.3390/cells12010119.
“Estimates of Amyloid Onset May Predict Alzheimer’s Progression | National Institute on Aging.” National Institute on Aging, NIH, 2 Feb. 2023, www.nia.nih.gov/news/estimates-amyloid-onset-may-predict-alzheimers-progression.
Findley, Caleigh. “What Are Alzheimer’s Plaques and Tangles?” BrightFocus Foundation, 8 Jan. 2025, www.brightfocus.org/resource/what-are-alzheimers-plaques-and-tangles/.
Fortier, Mélanie, et al. “A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6‐month RCT.” Alzheimer’s & Dementia, vol. 17, no. 3, 26 Oct. 2020, pp. 543–552, https://doi.org/10.1002/alz.12206.
Henderson, Samuel T, et al. “Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, Multicenter Trial.” Nutrition & Metabolism, vol. 6, no. 1, 10 Aug. 2009, p. 31, https://doi.org/10.1186/1743-7075-6-31.
Herrup, Karl. “The case for rejecting the amyloid cascade hypothesis.” Nature Neuroscience, vol. 18, no. 6, 26 May 2015, pp. 794–799, https://doi.org/10.1038/nn.4017.
Hsu, Yu-Chieh, et al. “Efficacy of probiotic supplements on brain-derived neurotrophic factor, inflammatory biomarkers, oxidative stress and cognitive function in patients with Alzheimer's dementia: A 12-week randomized, double-blind active-controlled study.” Nutrients, vol. 16, no. 1, 20 Dec. 2023, p. 16, https://doi.org/10.3390/nu16010016.
Jiang, Xueqin, et al. “Fecal microbiota transplantation improves cognitive function of a mouse model of Alzheimer's disease.” CNS Neuroscience & Therapeutics, vol. 31, no. 2, 17 Feb. 2025, https://doi.org/10.1111/cns.70259.
Liang, Xinyan, et al. “Microglia and its genetics in Alzheimer's disease.” Current Alzheimer Research, vol. 18, no. 9, Aug. 2021, pp. 676–688, https://doi.org/10.2174/1567205018666211105140732.
Medeiros, Rodrigo, et al. “The role of tau in Alzheimer's disease and related disorders.” CNS Neuroscience & Therapeutics, vol. 17, no. 5, 23 Sept. 2011, pp. 514–524, https://doi.org/10.1111/j.1755-5949.2010.00177.x.
Miao, Jifei, et al. “Microglia in Alzheimer's disease: Pathogenesis, mechanisms, and therapeutic potentials.” Frontiers in Aging Neuroscience, vol. 15, 15 June 2023, https://doi.org/10.3389/fnagi.2023.1201982.
Muzio, Luca, et al. “Microglia in neuroinflammation and neurodegeneration: From understanding to therapy.” Frontiers in Neuroscience, vol. 15, 24 Sept. 2021, https://doi.org/10.3389/fnins.2021.742065.
Nhan, Hoang S., et al. “The multifaceted nature of amyloid precursor protein and its proteolytic fragments: Friends and foes.” Acta Neuropathologica, vol. 129, no. 1, 7 Oct. 2014, pp. 1–19, https://doi.org/10.1007/s00401-014-1347-2.
Nimgampalle, Mallikarjuna. “Anti-alzheimer properties of probiotic, lactobacillus plantarum MTCC 1325 in Alzheimer's disease induced albino rats.” JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 1 Aug. 2017, https://doi.org/10.7860/jcdr/2017/26106.10428.
Phillips, Matthew C., et al. “Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease.” Alzheimer’s Research & Therapy, vol. 13, no. 1, 23 Feb. 2021, https://doi.org/10.1186/s13195-021-00783-x.
Prajapati, Santosh Kumar, et al. “Protection of alzheimer’s disease progression by a human-origin probiotics cocktail.” Scientific Reports, vol. 15, no. 1, 10 Jan. 2025, https://doi.org/10.1038/s41598-024-84780-8.
Qin, Qi, et al. “Trem2, Microglia, and alzheimer’s disease.” Mechanisms of Ageing and Development, vol. 195, Apr. 2021, p. 111438, https://doi.org/10.1016/j.mad.2021.111438.
Qiu, Tian, et al. “Aβ42 and aβ40: Similarities and differences.” Journal of Peptide Science, vol. 21, no. 7, 28 May 2015, pp. 522–529, https://doi.org/10.1002/psc.2789.
Rabinovici, G.D., et al. “Donanemab: Appropriate use recommendations.” The Journal of Prevention of Alzheimer’s Disease, vol. 12, no. 5, 10 May 2025, p. 100150, https://doi.org/10.1016/j.tjpad.2025.100150.
Singh, Ravneet. “Cholinesterase Inhibitors.” StatPearls [Internet]., U.S. National Library of Medicine, 17 July 2023, www.ncbi.nlm.nih.gov/books/NBK544336/.
“United States 2025: Knowledge and Behaviors about Microbiota.” Biocodex Microbiota Institute, 4 Dec. 2025, www.biocodexmicrobiotainstitute.com/en/international-microbiota-observatory/2025/united-states.
Upadhyay, Prabhat, et al. “Gut microbiome rewiring via fecal transplants: Uncovering therapeutic avenues in Alzheimer's disease models.” BMC Neuroscience, vol. 26, no. 1, 4 July 2025, https://doi.org/10.1186/s12868-025-00953-9.
Villegas, Sandra, et al. “Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease.” Neural Regeneration Research, vol. 17, no. 8, Aug. 2022, p. 1666, https://doi.org/10.4103/1673-5374.332127.
Zhang, Can, et al. “Amyloid-β production via cleavage of amyloid-β protein precursor is modulated by cell density.” Journal of Alzheimer’s Disease, vol. 22, no. 2, 1 Oct. 2010, pp. 683–694, https://doi.org/10.3233/jad-2010-100816.
Zhou, Yixiu, et al. “Alzheimer’s disease: Amyloid-based pathogenesis and potential therapies.” Cell Stress, vol. 2, no. 7, 9 July 2018, pp. 150–161, https://doi.org/10.15698/cst2018.07.143.
Downloads
Posted
Categories
License
Copyright (c) 2026 Celine Pei, Adeline Walsh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
